Integrative Management of Pancreatic Cancer (PDAC): Emerging Complementary Agents and Modalities

References

• Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. Lancet. 2020;395(10242):2008–20. doi:https://doi.org/10.1016/S0140-6736(20)30974-0
   PubMed Web of Science ®Google Scholar
• Ferrone CR, Ryan DP. Pancreatic cancer: a time to change. Ann Surg. 2020;271(6):1003–4. doi:https://doi.org/10.1097/SLA.0000000000003910
   PubMed Web of Science ®Google Scholar
• Sarantis P, Koustas E, Papadimitropoulou A, Papavassiliou AG, Karamouzis MV. Pancreatic ductal adenocarcinoma: treatment hurdles, tumor microenvironment and immunotherapy. World J Gastrointest Oncol. 2020;12(2):173–81. doi:https://doi.org/10.4251/wjgo.v12.i2.173
   PubMed Web of Science ®Google Scholar
• Ushio J, Kanno A, Ikeda E, Ando K, Nagai H, Miwata T, Kawasaki Y, Tada Y, Yokoyama K, Numao N, et al. Pancreatic ductal adenocarcinoma: epidemiology and risk factors. Diagnostics. 2021;11(3):562. doi:https://doi.org/10.3390/diagnostics11030562
   Web of Science ®Google Scholar
• Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21. doi:https://doi.org/10.1158/0008-5472.CAN-14-0155
   PubMed Web of Science ®Google Scholar
• Lu F, Poruk KE, Weiss MJ. Surgery for oligometastasis of pancreatic cancer. Chin J Cancer Res. 2015;27(4):358–67.
   PubMed Web of Science ®Google Scholar
• Raufi AG, Manji GA, Chabot JA, Bates SE. Neoadjuvant treatment for pancreatic cancer. Semin Oncol. 2019;46(1):19–27. doi:https://doi.org/10.1053/j.seminoncol.2018.12.002
   PubMed Web of Science ®Google Scholar
• El Hassouni B, Li Petri G, Liu DSK, et al. Pharmacogenetics of treatments for pancreatic cancer. Expert Opin Drug Metab Toxicol. 2019;15(6):437–47. doi:https://doi.org/10.1080/17425255.2019.1620731
   PubMed Web of Science ®Google Scholar
• Mini E, Nobili S, Caciagli B, Landini I, Mazzei T. Cellular pharmacology of gemcitabine. Ann Oncol. 2006;17 (Suppl 5):v7–v12. doi:https://doi.org/10.1093/annonc/mdj941
   PubMed Web of Science ®Google Scholar
• Marasini B, Sahu RP. Natural anti-cancer agents: implications in gemcitabine-resistant pancreatic cancer treatment. Mini Rev Med Chem. 2017;17(11):920–7.
   PubMed Web of Science ®Google Scholar
• Lin SR, Chang CH, Hsu CF, et al. Natural compounds as potential adjuvants to cancer therapy: preclinical evidence. Br J Pharmacol. 2020;177(6):1409–23. doi:https://doi.org/10.1111/bph.14816
   PubMed Web of Science ®Google Scholar
• Drozdoff L, Klein E, Kiechle M, Paepke D. Use of biologically-based complementary medicine in breast and gynecological cancer patients during systemic therapy. BMC Complement Altern Med. 2018;18(1):259. doi:https://doi.org/10.1186/s12906-018-2325-3
   PubMed Web of Science ®Google Scholar
• Shalom-Sharabi I, Frenkel M, Caspi O, et al. Integrative oncology in supportive cancer care in Israel. Integr Cancer Ther. 2018;17(3):697–706. doi:https://doi.org/10.1177/1534735418764839
   PubMed Web of Science ®Google Scholar
• Keene MR, Heslop IM, Sabesan SS, Glass BD. Complementary and alternative medicine use in cancer: a systematic review. Complement Ther Clin Pract. 2019;35:33–47. doi:https://doi.org/10.1016/j.ctcp.2019.01.004
   PubMed Web of Science ®Google Scholar
• Mittelman SD. The role of diet in cancer prevention and chemotherapy efficacy. Annu Rev Nutr. 2020;40:273–97. doi:https://doi.org/10.1146/annurev-nutr-013120-041149
   PubMed Web of Science ®Google Scholar
• Jentzsch V, Davis JAA, Djamgoz MBA. Pancreatic cancer (PDAC): introduction of evidence-based complementary measures into integrative clinical management. Cancers. 2020;12(11):3096. doi:https://doi.org/10.3390/cancers12113096
   PubMed Web of Science ®Google Scholar
• Supic G, Jagodic M, Magic Z. Epigenetics: a new link between nutrition and cancer. Nutr Cancer. 2013;65(6):781–92. doi:https://doi.org/10.1080/01635581.2013.805794
   PubMed Web of Science ®Google Scholar
• Tiffon C. The impact of nutrition and environmental epigenetics on human health and disease. IJMS. 2018;19(11):3425. doi:https://doi.org/10.3390/ijms19113425
   Web of Science ®Google Scholar
• Hernando-Requejo O, García de Quinto H, Rubio Rodríguez MC. Nutrition as an epigenetic factor in develops of cancer. Nutr Hosp. 2019;36:53–7. doi:https://doi.org/10.20960/nh.02810
   PubMed Web of Science ®Google Scholar
• Nasir A, Bullo MMH, Ahmed Z, et al. Nutrigenomics: epigenetics and cancer prevention: a comprehensive review. Crit Rev Food Sci Nutr. 2020;60(8):1375–87. doi:https://doi.org/10.1080/10408398.2019.1571480
   PubMed Web of Science ®Google Scholar
• Campbell TC. The past, present, and future of nutrition and cancer: part 1—was a nutritional association acknowledged a century ago?Nutr Cancer. 2017;69(5):811–7. doi:https://doi.org/10.1080/01635581.2017.1317823
   PubMed Web of Science ®Google Scholar
• Azimi H, Khakshur AA, Abdollahi M, Rahimi R. Potential new pharmacological agents derived from medicinal plants for the treatment of pancreatic cancer. Pancreas. 2015;44(1):11–5. doi:https://doi.org/10.1097/MPA.0000000000000175
   PubMed Web of Science ®Google Scholar
• Lu PY, Shu L, Shen SS, Chen XJ, Zhang XY. Dietary patterns and pancreatic cancer risk: a meta-analysis. Nutrients. 2017;9(1):38. doi:https://doi.org/10.3390/nu9010038
   PubMed Web of Science ®Google Scholar
• Weisbeck A, Jansen RJ. Nutrients and the pancreas: an epigenetic perspective. Nutrients. 2017;9(3):283. doi:https://doi.org/10.3390/nu9030283
   PubMed Web of Science ®Google Scholar
• Lohse I, Wildermuth E, Brothers SP. Naturally occurring compounds as pancreatic cancer therapeutics. Oncotarget. 2018;9(83):35448–57. doi:https://doi.org/10.18632/oncotarget.26234
   PubMedGoogle Scholar
• Ko J-H, Sethi G, Um J-Y, Shanmugam MK, Arfuso F, Kumar AP, Bishayee A, Ahn KS. The role of resveratrol in cancer therapy. IJMS. 2017;18(12):2589. doi:https://doi.org/10.3390/ijms18122589
   Web of Science ®Google Scholar
• Zhou C, Qian W, Ma J, et al. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Cell Prolif. 2019;52(1):e12514. doi:https://doi.org/10.1111/cpr.12514
   PubMed Web of Science ®Google Scholar
• Hoca M, Becer E, Kabadayı H, Yücecan S, Vatansever HS. The effect of resveratrol and quercetin on epithelial-mesenchymal transition in pancreatic cancer stem cell. Nutr Cancer. 2020;72(7):1231–42. doi:https://doi.org/10.1080/01635581.2019.1670853
   PubMed Web of Science ®Google Scholar
• Fu J, Shrivastava A, Shrivastava SK, Srivastava RK, Shankar S. Triacetyl resveratrol upregulates miRNA‑200 and suppresses the Shh pathway in pancreatic cancer: a potential therapeutic agent. Int J Oncol. 2019;54(4):1306–16. doi:https://doi.org/10.3892/ijo.2019.4700
   PubMed Web of Science ®Google Scholar
• Cheng L, Yan B, Chen K, et al. Resveratrol-induced downregulation of NAF-1 enhances the sensitivity of pancreatic cancer cells to gemcitabine via the ROS/Nrf2 signaling pathways. Oxid Med Cell Longev. 2018;2018:9482018. doi:https://doi.org/10.1155/2018/9482018
   PubMed Web of Science ®Google Scholar
• Jiang Z, Chen X, Chen K, Sun L, Gao L, Zhou C, Lei M, Duan W, Wang Z, Ma Q, et al. YAP inhibition by resveratrol via activation of AMPK enhances the sensitivity of pancreatic cancer cells to gemcitabine. Nutrients. 2016;8(10):546. doi:https://doi.org/10.3390/nu8100546
   PubMed Web of Science ®Google Scholar
• Harikumar KB, Kunnumakkara AB, Sethi G, et al. Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic. Int J Cancer. 2010;127(2):257–68.
   PubMed Web of Science ®Google Scholar
• Gupta SC, Kannappan R, Reuter S, Kim JH, Aggarwal BB. Chemosensitization of tumors by resveratrol. Ann N Y Acad Sci. 2011;1215:150–60. doi:https://doi.org/10.1111/j.1749-6632.2010.05852.x
   PubMed Web of Science ®Google Scholar
• Xu Q, Zong L, Chen X, Jiang Z, Nan L, Li J, Duan W, Lei J, Zhang L, Ma J, et al. Resveratrol in the treatment of pancreatic cancer. Ann NY Acad Sci. 2015;1348(1):10–9. doi:https://doi.org/10.1111/nyas.12837
   PubMed Web of Science ®Google Scholar
• Hsu YH, Chen SY, Wang SY, Lin JA, Yen GC. Pterostilbene enhances cytotoxicity and chemosensitivity in human pancreatic cancer cells. Biomolecules. 2020;10(5):709. doi:https://doi.org/10.3390/biom10050709
   PubMed Web of Science ®Google Scholar
• Vendrely V, Amintas S, Noel C, et al. Combination treatment of resveratrol and capsaicin radiosensitizes pancreatic tumor cells by unbalancing DNA repair response to radiotherapy towards cell death. Cancer Lett. 2019;451:1–10. doi:https://doi.org/10.1016/j.canlet.2019.02.038
   PubMed Web of Science ®Google Scholar
• Vendrely V, Peuchant E, Buscail E, et al. Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. Cancer Lett. 2017;390:91–102. doi:https://doi.org/10.1016/j.canlet.2017.01.002
   PubMed Web of Science ®Google Scholar
• Xiao Q, Zhu W, Feng W, et al. A Review of resveratrol as a potent chemoprotective and synergistic agent in cancer chemotherapy. Front Pharmacol. 2019;9:1534.
   PubMed Web of Science ®Google Scholar
• Filippini T, Malavolti M, Borrelli F, et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev. 2020;3(3):CD005004.
   PubMed Web of Science ®Google Scholar
• Musial C, Kuban-Jankowska A, Gorska-Ponikowska M. Beneficial properties of green tea catechins. IJMS. 2020;21(5):1744. doi:https://doi.org/10.3390/ijms21051744
   Web of Science ®Google Scholar
• Chang B, Sang L, Wang Y, Tong J, Wang BY. Consumption of tea and risk for pancreatic cancer: a meta-analysis of published epidemiological studies. Nutr Cancer. 2014;66(7):1109–23. doi:https://doi.org/10.1080/01635581.2014.951730
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang W, Sun L, et al. Green tea drinking and risk of pancreatic cancer: a large-scale, population-based case-control study in urban Shanghai. Cancer Epidemiol. 2012;36(6):e354–e358. doi:https://doi.org/10.1016/j.canep.2012.08.004
   PubMed Web of Science ®Google Scholar
• Zeng JL, Li ZH, Wang ZC, Zhang HL. Green tea consumption and risk of pancreatic cancer: a meta-analysis. Nutrients. 2014;6(11):4640–50. doi:https://doi.org/10.3390/nu6114640
   PubMed Web of Science ®Google Scholar
• Abe SK, Inoue M. Green tea and cancer and cardiometabolic diseases: a review of the current epidemiological evidence. Eur J Clin Nutr. 2020. doi:https://doi.org/10.1038/s41430-020-00710-7
   PubMed Web of Science ®Google Scholar
• Khan N, Mukhtar H. Tea polyphenols in promotion of human health. Nutrients. 2018;11(1):39. doi:https://doi.org/10.3390/nu11010039
   PubMed Web of Science ®Google Scholar
• Lin Y, Shi D, Su B, et al. The effect of green tea supplementation on obesity: a systematic review and dose–response meta‐analysis of randomized controlled trials. Phytother Res. 2020;34(10):2459–2470. doi:https://doi.org/10.1002/ptr.66971–1.
   PubMed Web of Science ®Google Scholar
• Babu BI, Malleo G, Genovese T, et al. Green tea polyphenols ameliorate pancreatic injury in cerulein-induced murine acute pancreatitis. Pancreas. 2009;38(8):954–67. doi:https://doi.org/10.1097/MPA.0b013e3181b28d11
   PubMed Web of Science ®Google Scholar
• Bimonte S, Leongito M, Barbieri A, et al. Inhibitory effect of (-)-epigallocatechin-3-gallate and bleomycin on human pancreatic cancer MiaPaca-2 cell growth. Infect Agent Cancer. 2015;10:22.
   PubMed Web of Science ®Google Scholar
• Li L, Leung PS. Use of herbal medicines and natural products: an alternative approach to overcoming the apoptotic resistance of pancreatic cancer. Int J Biochem Cell Biol. 2014;53:224–36. doi:https://doi.org/10.1016/j.biocel.2014.05.021
   PubMed Web of Science ®Google Scholar
• Tang SN, Fu J, Nall D, Rodova M, Shankar S, Srivastava RK. Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics. Int J Cancer. 2012;131(1):30–40. doi:https://doi.org/10.1002/ijc.26323
   PubMed Web of Science ®Google Scholar
• Wei R, Penso NEC, Hackman RM, Wang Y, Mackenzie GG. Epigallocatechin-3-gallate (EGCG) suppresses pancreatic cancer cell growth, invasion, and migration partly through the inhibition of akt pathway and epithelial-mesenchymal transition: enhanced efficacy when combined with gemcitabine. Nutrients. 2019a;11(8):1856. doi:https://doi.org/10.3390/nu11081856
   PubMed Web of Science ®Google Scholar
• Wei R, Hackman RM, Wang Y, Mackenzie GG. Targeting glycolysis with epigallocatechin-3-gallate enhances the efficacy of chemotherapeutics in pancreatic cancer cells and xenografts. Cancers (Basel). 2019b;11(10):1496. doi:https://doi.org/10.3390/cancers11101496
   PubMed Web of Science ®Google Scholar
• Lin HL, An QZ, Wang QZ, Liu CX. Folate intake and pancreatic cancer risk: an overall and dose-response meta-analysis. Public Health. 2013;127(7):607–13. doi:https://doi.org/10.1016/j.puhe.2013.04.008
   PubMed Web of Science ®Google Scholar
• Gong Z, Holly EA, Bracci PM. Intake of folate, vitamins B6, B12 and methionine and risk of pancreatic cancer in a large population-based case-control study. Cancer Causes Control. 2009;20(8):1317–25. doi:https://doi.org/10.1007/s10552-009-9352-9
   PubMed Web of Science ®Google Scholar
• Park JY, Bueno-de-Mesquita HB, Ferrari P, Weiderpass E, Batlle J, Tjønneland A, Kyro C, Rebours V, Boutron-Ruault M-C, Mancini FR, et al. Dietary folate intake and pancreatic cancer risk: results from the European prospective investigation into cancer and nutrition. Int J Cancer. 2019;144(7):1511–21. doi:https://doi.org/10.1002/ijc.31830
   PubMed Web of Science ®Google Scholar
• Yallew W, Bamlet WR, Oberg AL, Anderson KE, Olson JE, Sinha R, Petersen GM, Stolzenberg-Solomon RZ, Jansen RJ. Association between alcohol consumption, folate intake, and risk of pancreatic cancer: a case-control study. Nutrients. 2017;9(5):0448. doi:https://doi.org/10.3390/nu9050448
   PubMed Web of Science ®Google Scholar
• Arendt JFH, Sørensen HT, Horsfall LJ, Petersen I. Elevated vitamin B12 levels and cancer risk in uk primary care: a THIN Database Cohort Study. Cancer Epidemiol Biomarkers Prev. 2019;28(4):814–21. doi:https://doi.org/10.1158/1055-9965.EPI-17-1136
   PubMed Web of Science ®Google Scholar
• Lin CH, Lu WC, Wang CW, Chan YC, Chen MK. Capsaicin induces cell cycle arrest and apoptosis in human KB cancer cells. BMC Complement Altern Med. 2013;13:46. doi:https://doi.org/10.1186/1472-6882-13-46
   PubMed Web of Science ®Google Scholar
• Zhang JH, Lai FJ, Chen H, Luo J, Zhang R-Y, Bu H-Q, Wang Z-H, Lin H-H, Lin S-Z. Involvement of the phosphoinositide 3-kinase/Akt pathway in apoptosis induced by capsaicin in the human pancreatic cancer cell line PANC-1. Oncol Lett. 2013;5(1):43–8. doi:https://doi.org/10.3892/ol.2012.991
   PubMed Web of Science ®Google Scholar
• Pramanik KC, Boreddy SR, Srivastava SK. Role of mitochondrial electron transport chain complexes in capsaicin mediated oxidative stress leading to apoptosis in pancreatic cancer cells. PLoS One. 2011;6(5):e20151. doi:https://doi.org/10.1371/journal.pone.0020151
   PubMed Web of Science ®Google Scholar
• Boreddy SR, Srivastava SK. Pancreatic cancer chemoprevention by phytochemicals. Cancer Lett. 2013;334(1):86–94. doi:https://doi.org/10.1016/j.canlet.2012.10.020
   PubMed Web of Science ®Google Scholar
• Lan CY, Chen SY, Kuo CW, Lu CC, Yen GC. Quercetin facilitates cell death and chemosensitivity through RAGE/PI3K/AKT/mTOR axis in human pancreatic cancer cells. J Food Drug Anal. 2019;27(4):887–96. doi:https://doi.org/10.1016/j.jfda.2019.07.001
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee HB, Jung GO, et al. Effect of quercetin on apoptosis of PANC-1 cells. J Korean Surg Soc. 2013;85(6):249–60. doi:https://doi.org/10.4174/jkss.2013.85.6.249
   PubMedGoogle Scholar
• Yu D, Ye T, Xiang Y, Shi Z, Zhang J, Lou B, Zhang F, Chen B, Zhou M. Quercetin inhibits epithelial-mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial-mesenchymal transition, expression of MMP by inhibiting STAT3 signaling in pancreatic cancer cells. Onco Targets Ther. 2017;10:4719–29. doi:https://doi.org/10.2147/OTT.S136840
   PubMed Web of Science ®Google Scholar
• Nwaeburu CC, Bauer N, Zhao Z, et al. Up-regulation of microRNA let-7c by quercetin inhibits pancreatic cancer progression by activation of Numbl. Oncotarget. 2016; 7:58367–80. doi:https://doi.org/10.18632/oncotarget.11122
   PubMedGoogle Scholar
• Nwaeburu CC, Abukiwan A, Zhao Z, Herr I. Quercetin-induced miR-200b-3p regulates the mode of self-renewing divisions in pancreatic cancer. Mol Cancer. 2017;16(1):23. doi:https://doi.org/10.1186/s12943-017-0589-8
   PubMed Web of Science ®Google Scholar
• Serri C, Quagliariello V, Iaffaioli RV, et al. Combination therapy for the treatment of pancreatic cancer through hyaluronic acid-decorated nanoparticles loaded with quercetin and gemcitabine: a preliminary in vitro study. J Cell Physiol. 2019;234(4):4959–69. doi:https://doi.org/10.1002/jcp.27297
   PubMed Web of Science ®Google Scholar
• Liu ZJ, Xu W, Han J, et al. Quercetin induces apoptosis and enhances gemcitabine therapeutic efficacy against gemcitabine-resistant cancer cells. Anticancer Drugs. 2020;31(7):684–92. doi:https://doi.org/10.1097/CAD.0000000000000933
   PubMed Web of Science ®Google Scholar
• Lee J, Lee J, Kim SJ, Kim JH. Quercetin-3-O-glucoside suppresses pancreatic cancer cell migration induced by tumor-deteriorated growth factors in vitro. Oncol Rep. 2016;35(4):2473–9. doi:https://doi.org/10.3892/or.2016.4598
   PubMed Web of Science ®Google Scholar
• Angst E, Park JL, Moro A, et al. The flavonoid quercetin inhibits pancreatic cancer growth in vitro and in vivo. Pancreas. 2013;42(2):223–9. doi:https://doi.org/10.1097/MPA.0b013e318264ccae
   PubMed Web of Science ®Google Scholar
• Li LY, Luo Y, Lu MD, et al. Cruciferous vegetable consumption and the risk of pancreatic cancer: a meta-analysis. World J Surg Oncol. 2015;13:44. doi:https://doi.org/10.1186/s12957-015-0454-4
   PubMed Web of Science ®Google Scholar
• Appari M, Babu KR, Kaczorowski A, Gross W, Herr I. Sulforaphane, quercetin and catechins complement each other in elimination of advanced pancreatic cancer by miR-let-7 induction and K-ras inhibition. Int J Oncol. 2014;45(4):1391–400. doi:https://doi.org/10.3892/ijo.2014.2539
   PubMed Web of Science ®Google Scholar
• Lozanovski VJ, Polychronidis G, Gross W, et al. Broccoli sprout supplementation in patients with advanced pancreatic cancer is difficult despite positive effects: results from the POUDER pilot study. Invest New Drugs. 2020;38:776–84. doi:https://doi.org/10.1007/s10637-019-00826-z
   PubMed Web of Science ®Google Scholar
• Kallifatidis G, Labsch S, Rausch V, et al. Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate. Mol Ther. 2011;19(1):188–95. doi:https://doi.org/10.1038/mt.2010.216
   PubMed Web of Science ®Google Scholar
• Naumann P, Liermann J, Fortunato F, et al. Sulforaphane enhances irradiation effects in terms of perturbed cell cycle progression and increased DNA damage in pancreatic cancer cells. PLoS One. 2017;12(7):e0180940. doi:https://doi.org/10.1371/journal.pone.0180940
   PubMed Web of Science ®Google Scholar
• Kamal MM, Akter S, Lin CN, Nazzal S. Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems. Arch Pharm Res. 2020;43(4):371–84. doi:https://doi.org/10.1007/s12272-020-01225-2
   PubMed Web of Science ®Google Scholar
• Lee Y-R, Chen M, Lee JD, Zhang J, Lin S-Y, Fu T-M, Chen H, Ishikawa T, Chiang S-Y, Katon J, et al. Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science. 2019;364(6441):eaau0159. doi:https://doi.org/10.1126/science.aau0159
   PubMed Web of Science ®Google Scholar
• Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361. doi:https://doi.org/10.1101/cshperspect.a030361
   PubMed Web of Science ®Google Scholar
• Di Sebastiano KM, Pinthus JH, Duivenvoorden WCM, Mourtzakis M. Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise. Obes Rev. 2018;19(7):1008–16. doi:https://doi.org/10.1111/obr.12674
   PubMed Web of Science ®Google Scholar
• Li SH, Fu J, Watkins DN, Srivastava RK, Shankar S. Sulforaphane regulates self-renewal of pancreatic cancer stem cells through the modulation of Sonic hedgehog-GLI pathway. Mol Cell Biochem. 2013;373(1-2):217–27. doi:https://doi.org/10.1007/s11010-012-1493-6
   PubMed Web of Science ®Google Scholar
• Kallifatidis G, Rausch V, Baumann B, et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut. 2009;58(7):949–63. doi:https://doi.org/10.1136/gut.2008.149039
   PubMed Web of Science ®Google Scholar
• Li Y, Go VL, Sarkar FH. The role of nutraceuticals in pancreatic cancer prevention and therapy: targeting cellular signaling, microRNAs, and epigenome. Pancreas. 2015;44(1):1–10. doi:https://doi.org/10.1097/MPA.0000000000000257
   PubMed Web of Science ®Google Scholar
• Li Y, Wang Y, Kong R, et al. Dihydroartemisinin suppresses pancreatic cancer cells via a microRNA-mRNA regulatory network. Oncotarget. 2016;7(38):62460–73. doi:https://doi.org/10.18632/oncotarget.11517
   PubMedGoogle Scholar
• Chen H, Sun B, Pan S, Jiang H, Sun X. Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivo. Anticancer Drugs. 2009;20(2):131–40. doi:https://doi.org/10.1097/CAD.0b013e3283212ade
   PubMed Web of Science ®Google Scholar
• Wang SJ, Gao Y, Chen H, et al. Dihydroartemisinin inactivates NF-kappaB and potentiates the anti-tumor effect of gemcitabine on pancreatic cancer both in vitro and in vivo. Cancer Lett. 2010;293(1):99–108. doi:https://doi.org/10.1016/j.canlet.2010.01.001
   PubMed Web of Science ®Google Scholar
• Jia G, Kong R, Ma Z-B, Han B, Wang Y-W, Pan S-H, Li Y-H, Sun B. The activation of c-Jun NH2-terminal kinase is required for dihydroartemisinin-induced autophagy in pancreatic cancer cells. J Exp Clin Cancer Res. 2014;33(1):8. doi:https://doi.org/10.1186/1756-9966-33-8
   PubMed Web of Science ®Google Scholar
• Crespo-Ortiz MP, Wei MQ. Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol. 2012;2012:247597. doi:https://doi.org/10.1155/2012/247597
   PubMedGoogle Scholar
• Zhou ZH, Chen FX, Xu WR, et al. Enhancement effect of dihydroartemisinin on human γδ T cell proliferation and killing pancreatic cancer cells. Int Immunopharmacol. 2013;17(3):850–7. doi:https://doi.org/10.1016/j.intimp.2013.09.015
   PubMed Web of Science ®Google Scholar
• Kong R, Jia G, Cheng ZX, et al. Dihydroartemisinin enhances Apo2L/TRAIL-mediated apoptosis in pancreatic cancer cells via ROS-mediated up-regulation of death receptor 5. PLoS One. 2012;7(5):e37222. doi:https://doi.org/10.1371/journal.pone.0037222
   PubMed Web of Science ®Google Scholar
• Hou J, Wang D, Zhang R, Wang H. Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clin Cancer Res. 2008;14(17):5519–30. doi:https://doi.org/10.1158/1078-0432.CCR-08-0197
   PubMed Web of Science ®Google Scholar
• Parasramka MA, Gupta SV. Synergistic effect of garcinol and curcumin on antiproliferative and apoptotic activity in pancreatic cancer cells. J Oncol. 2012;2012:1–8. doi:https://doi.org/10.1155/2012/709739
   Google Scholar
• Parasramka MA, Ali S, Banerjee S, Deryavoush T, Sarkar FH, Gupta S. Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures. Mol Nutr Food Res. 2013;57(2):235–48. doi:https://doi.org/10.1002/mnfr.201200297
   PubMed Web of Science ®Google Scholar
• Huang CC, Lin CM, Huang YJ, et al. Garcinol downregulates Notch1 signaling via modulating miR-200c and suppresses oncogenic properties of PANC-1 cancer stem-like cells. Biotechnol Appl Biochem. 2017;64(2):165–73. doi:https://doi.org/10.1002/bab.1446
   PubMed Web of Science ®Google Scholar
• Saadat N, Akhtar S, Goja A, et al. Dietary garcinol arrests pancreatic cancer in p53 and K-ras conditional mutant mouse model. Nutr Cancer. 2018;70(7):1075–87. doi:https://doi.org/10.1080/01635581.2018.1502327
   PubMed Web of Science ®Google Scholar
• Tavakkoli A, Mahdian V, Razavi BM, Hosseinzadeh H. Review on clinical trials of black seed (Nigella sativa) and its active constituent, thymoquinone. J Pharmacopuncture. 2017;20(3):179–93. doi:https://doi.org/10.3831/KPI.2017.20.021
   PubMed Web of Science ®Google Scholar
• Rauf A, Imran M, Khan IA, et al. Anticancer potential of quercetin: a comprehensive review. Phytother Res. 2018;32(11):2109–30. doi:https://doi.org/10.1002/ptr.6155
   PubMed Web of Science ®Google Scholar
• Mahmoud YK, Abdelrazek HMA. Cancer: thymoquinone antioxidant/pro-oxidant effect as potential anticancer remedy. Biomed Pharmacother. 2019;115:108783. doi:https://doi.org/10.1016/j.biopha.2019.108783
   PubMed Web of Science ®Google Scholar
• Torres MP, Ponnusamy MP, Chakraborty S, et al. Effects of thymoquinone in the expression of mucin 4 in pancreatic cancer cells: implications for the development of novel cancer therapies. Mol Cancer Ther. 2010;9(5):1419–31. doi:https://doi.org/10.1158/1535-7163.MCT-10-0075
   PubMed Web of Science ®Google Scholar
• Pandita A, Kumar B, Manvati S, et al. Synergistic combination of gemcitabine and dietary molecule induces apoptosis in pancreatic cancer cells and down regulates PKM2 expression. PLoS One. 2014;9(9):e107154. doi:https://doi.org/10.1371/journal.pone.0107154
   PubMed Web of Science ®Google Scholar
• Mu GG, Zhang LL, Li HY, Liao Y, Yu HG. Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of Notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer. Dig Dis Sci. 2015;60(4):1067–80. doi:https://doi.org/10.1007/s10620-014-3394-x
   PubMed Web of Science ®Google Scholar
• Khan MA, Tania M, Fu S, Fu J. Thymoquinone, as an anticancer molecule: from basic research to clinical investigation. Oncotarget. 2017;8(31):51907–19. doi:https://doi.org/10.18632/oncotarget.17206
   PubMedGoogle Scholar
• Relles D, Chipitsyna GI, Gong Q, Yeo CJ, Arafat HA. Thymoquinone promotes pancreatic cancer cell death and reduction of tumor size through combined inhibition of histone deacetylation and induction of histone acetylation. Adv Prev Med. 2016;2016:1–9. doi:https://doi.org/10.1155/2016/1407840
   Google Scholar
• Pan FP, Zhou HK, Bu HQ, et al. Emodin enhances the demethylation by 5-Aza-CdR of pancreatic cancer cell tumor-suppressor genes P16, RASSF1A and ppENK. Oncol Rep. 2016;35(4):1941–9. doi:https://doi.org/10.3892/or.2016.4554
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen H, Liu DL, et al. Emodin sensitizes the gemcitabine-resistant cell line Bxpc-3/Gem to gemcitabine via downregulation of NF-κB and its regulated targets. Int J Oncol. 2013;42(4):1189–96. doi:https://doi.org/10.3892/ijo.2013.1839
   PubMed Web of Science ®Google Scholar
• Zhang H, Chen L, Bu HQ, et al. Effects of emodin on the demethylation of tumor-suppressor genes in pancreatic cancer PANC-1 cells. Oncol Rep. 2015;33(6):3015–23. doi:https://doi.org/10.3892/or.2015.3914
   PubMed Web of Science ®Google Scholar
• Lin SZ, Wei WT, Chen H, et al. Antitumor activity of emodin against pancreatic cancer depends on its dual role: promotion of apoptosis and suppression of angiogenesis. PLoS One. 2012;7(8):e42146. doi:https://doi.org/10.1371/journal.pone.0042146
   PubMed Web of Science ®Google Scholar
• Li N, Wang C, Zhang P, You S. Emodin inhibits pancreatic cancer EMT and invasion by up‑regulating microRNA‑1271. Mol Med Rep. 2018;18(3):3366–74.
   PubMed Web of Science ®Google Scholar
• Guo HC, Bu HQ, Luo J, et al. Emodin potentiates the antitumor effects of gemcitabine in PANC-1 pancreatic cancer xenograft model in vivo via inhibition of inhibitors of apoptosis. Int J Oncol. 2012;40(6):1849–57.
   PubMed Web of Science ®Google Scholar
• Wang ZH, Chen H, Guo HC, et al. Enhanced antitumor efficacy by the combination of emodin and gemcitabine against human pancreatic cancer cells via downregulation of the expression of XIAP in vitro and in vivo. Int J Oncol. 2011;39(5):1123–31.
   PubMed Web of Science ®Google Scholar
• Kim Y-S, Lee Y-M, Oh T-I, Shin D, Kim G-H, Kan S-Y, Kang H, Kim J, Kim B, Yim W, et al. Emodin sensitizes hepatocellular carcinoma cells to the anti-cancer effect of sorafenib through suppression of cholesterol metabolism. IJMS. 2018;19(10):3127. doi:https://doi.org/10.3390/ijms19103127
   Web of Science ®Google Scholar
• Hu L, Cui R, Liu H, Wang F. Emodin and rhein decrease levels of hypoxia-inducible factor-1α in human pancreatic cancer cells and attenuate cancer cachexia in athymic mice carrying these cells. Oncotarget. 2017;8(50):88008–20. doi:https://doi.org/10.18632/oncotarget.21330
   PubMedGoogle Scholar
• Huang X, Gao Y, Zhi X, Ta N, Jiang H, Zheng J. Association between vitamin A, retinol and carotenoid intake and pancreatic cancer risk: evidence from epidemiologic studies. Sci Rep. 2016;6:38936. doi:https://doi.org/10.1038/srep38936
   PubMed Web of Science ®Google Scholar
• Jeong Y, Lim JW, Kim H. Lycopene inhibits reactive oxygen species-mediated NF-κB signaling and induces apoptosis in pancreatic cancer cells. Nutrients. 2019;11(4):762. doi:https://doi.org/10.3390/nu11040762
   PubMed Web of Science ®Google Scholar
• Lv JC, Wang G, Pan SH, Bai XW, Sun B. Lycopene protects pancreatic acinar cells against severe acute pancreatitis by abating the oxidative stress through JNK pathway. Free Radic Res. 2015;49(2):151–63. doi:https://doi.org/10.3109/10715762.2014.988150
   PubMed Web of Science ®Google Scholar
• Zhu R, Chen B, Bai Y, et al. Lycopene in protection against obesity and diabetes: a mechanistic review. Pharmacol Res. 2020;159:104966. doi:https://doi.org/10.1016/j.phrs.2020.104966
   PubMed Web of Science ®Google Scholar
• Sahin K, Sahin N, Kucuk O. Lycopene and chemotherapy toxicity. Nutr Cancer. 2010;62(7):988–95. doi:https://doi.org/10.1080/01635581.2010.509838
   PubMed Web of Science ®Google Scholar
• van Steenwijk HP, Bast A, de Boer A. The role of circulating lycopene in low-grade chronic inflammation: a systematic review of the literature. Molecules. 2020;25(19):4378. doi:https://doi.org/10.3390/molecules25194378
   PubMed Web of Science ®Google Scholar
• Hoang BX, Han B, Shaw DG, Nimni M. Zinc as a possible preventive and therapeutic agent in pancreatic, prostate, and breast cancer. Eur J Cancer Prev. 2016;25(5):457–61. doi:https://doi.org/10.1097/CEJ.0000000000000194
   PubMed Web of Science ®Google Scholar
• Costello LC, Franklin RB. Decreased zinc in the development and progression of malignancy: an important common relationship and potential for prevention and treatment of carcinomas. Expert Opin Ther Targets. 2017;21(1):51–66. doi:https://doi.org/10.1080/14728222.2017.1265506
   PubMed Web of Science ®Google Scholar
• Jin H, Liu P, Wu Y, et al. Exosomal zinc transporter ZIP4 promotes cancer growth and is a novel diagnostic biomarker for pancreatic cancer. Cancer Sci. 2018;109(9):2946–56. doi:https://doi.org/10.1111/cas.13737
   PubMed Web of Science ®Google Scholar
• Li L, Gai X. The association between dietary zinc intake and risk of pancreatic cancer: a meta-analysis. Biosci Rep. 2017;37(3):BSR20170155.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao H, Xu Z, Cheng X. Zinc dysregulation in cancers and its potential as a therapeutic target. Cancer Biol Med. 2020;17(3):612–25. doi:https://doi.org/10.20892/j.issn.2095-3941.2020.0106
   PubMed Web of Science ®Google Scholar
• Costello LC, Franklin RB. Zinc: the wonder drug for the treatment of carcinomas. Acta Sci Cancer Biol. 2020;4(5):33–9.
   PubMedGoogle Scholar
• Chandran S, Patgiri B, Bedarkar P, Mathat D. Anticancer activity of Yashada Bhasma (bioactive nanoparticles of zinc): a human pancreatic cancer cell line study. Ayu. 2019;40(1):58–63. doi:https://doi.org/10.4103/ayu.AYU_239_17
   PubMedGoogle Scholar
• Shakri AR, Zhong TJ, Ma W, Coker C, Kim S, Calluori S, Scholze H, Szabolcs M, Caffrey T, Grandgenett PM, et al. Upregulation of ZIP14 and altered zinc homeostasis in muscles in pancreatic cancer cachexia. Cancers (Basel). 2019;12(1):3. doi:https://doi.org/10.3390/cancers12010003
   PubMed Web of Science ®Google Scholar
• Mohammad K, Zhou Z, Cave M, Barve A, McClain CJ. Zinc and liver disease. Nutr Clin Pract. 2012;27(1):8–20. doi:https://doi.org/10.1177/0884533611433534
   PubMed Web of Science ®Google Scholar
• Katayama K. Zinc and protein metabolism in chronic liver diseases. Nutr Res. 2020;74:1–9. doi:https://doi.org/10.1016/j.nutres.2019.11.009
   PubMed Web of Science ®Google Scholar
• Han X, Li J, Brasky TM, et al. Antioxidant intake and pancreatic cancer risk: the VITamins And Lifestyle (VITAL) study. Cancer. 2013;119(7):1314–20. doi:https://doi.org/10.1002/cncr.27936
   PubMed Web of Science ®Google Scholar
• Alexander MS, Cullen JJ. Treating pancreatic cancer: more antioxidants more problems?Expert Rev Gastroenterol Hepatol. 2018;12(9):849–51. doi:https://doi.org/10.1080/17474124.2018.1494572
   PubMed Web of Science ®Google Scholar
• Wang L, Wang J, Liu X, et al. Association between selenium intake and the risk of pancreatic cancer: a meta-analysis of observational studies. Biosci Rep. 2016;36(5):e00395.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Combs GF, Jr, Chattopadhyay A, Stolzenberg-Solomon R. Serum selenium and pancreatic cancer: a prospective study in the Prostate, Lung, Colorectal and Ovarian Cancer Trial cohort. Cancer Causes Control. 2019;30(5):457–64. doi:https://doi.org/10.1007/s10552-019-01147-5
   PubMed Web of Science ®Google Scholar
• Jacobs ET, Lance P, Mandarino LJ, et al. Selenium supplementation and insulin resistance in a randomized, clinical trial. BMJ Open Diabetes Res Care. 2019;7(1):e000613. doi:https://doi.org/10.1136/bmjdrc-2018-000613
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Ahmadi Z, Samarghandian S, et al. MicroRNA-mediated regulation of Nrf2 signaling pathway: implications in disease therapy and protection against oxidative stress. Life Sci. 2020;244:117329. doi:https://doi.org/10.1016/j.lfs.2020.117329
   PubMed Web of Science ®Google Scholar
• Hannon BA, Fairfield WD, Adams B, et al. Use and abuse of dietary supplements in persons with diabetes. Nutr Diabetes. 2020;10(1):14.
   PubMed Web of Science ®Google Scholar
• Behar A, Dennouni-Medjati N, Harek Y, et al. Selenium overexposure induces insulin resistance: in silico study. Diabetes Metab Syndr. 2020;14(6):1651–7. doi:https://doi.org/10.1016/j.dsx.2020.08.005
   PubMed Web of Science ®Google Scholar
• Schilling K, Larner F, Saad A, et al. Urine metallomics signature as an indicator of pancreatic cancer. Metallomics. 2020;12(5):752–7. doi:https://doi.org/10.1039/d0mt00061b
   PubMed Web of Science ®Google Scholar
• Dibaba D, Xun P, Yokota K, White E, He K. Magnesium intake and incidence of pancreatic cancer: the VITamins and Lifestyle study. Br J Cancer. 2015;113(11):1615–21. doi:https://doi.org/10.1038/bjc.2015.382
   PubMed Web of Science ®Google Scholar
• Rybarczyk P, Vanlaeys A, Brassart B, Dhennin-Duthille I, Chatelain D, Sevestre H, Ouadid-Ahidouch H, Gautier M. The transient receptor potential melastatin 7 channel regulates pancreatic cancer cell invasion through the Hsp90α/uPA/MMP2 pathway. Neoplasia. 2017;19(4):288–300. doi:https://doi.org/10.1016/j.neo.2017.01.004
   PubMed Web of Science ®Google Scholar
• Xie J, Cheng CS, Zhu XY, et al. Magnesium transporter protein solute carrier family 41 member 1 suppresses human pancreatic ductal adenocarcinoma through magnesium-dependent Akt/mTOR inhibition and bax-associated mitochondrial apoptosis. Aging (Albany NY). 2019;11(9):2681–98. doi:https://doi.org/10.18632/aging.101940
   PubMedGoogle Scholar
• Jansen RJ, Robinson DP, Stolzenberg-Solomon RZ, Bamlet WR, de Andrade M, Oberg AL, Rabe KG, Anderson KE, Olson JE, Sinha R, et al. Nutrients from fruit and vegetable consumption reduce the risk of pancreatic cancer. J Gastrointest Canc. 2013;44(2):152–61. doi:https://doi.org/10.1007/s12029-012-9441-y
   PubMedGoogle Scholar
• Hruby A, Guasch-Ferré M, Bhupathiraju SN, Manson JE, Willett WC, McKeown NM, Hu FB. Magnesium intake, quality of carbohydrates, and risk of type 2 diabetes: results from three U.S. cohorts. Dia Care. 2017;40(12):1695–702. doi:https://doi.org/10.2337/dc17-1143
   PubMed Web of Science ®Google Scholar
• Pan Q, Zhou R, Su M, Li R. The effects of plumbagin on pancreatic cancer: a mechanistic network pharmacology approach. Med Sci Monit. 2019;25:4648–54. doi:https://doi.org/10.12659/MSM.917240
   PubMed Web of Science ®Google Scholar
• Hafeez BB, Jamal MS, Fischer JW, Mustafa A, Verma AK. Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways. Int J Cancer. 2012;131(9):2175–86. doi:https://doi.org/10.1002/ijc.27478
   PubMed Web of Science ®Google Scholar
• Wang F, Wang Q, Zhou ZW, et al. Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells. Drug Des Devel Ther. 2015;9:537–60.
   PubMed Web of Science ®Google Scholar
• Subramaniam D, Kaushik G, Dandawate P, Anant S. Targeting cancer stem cells for chemoprevention of pancreatic cancer. Curr Med Chem. 2018;25(22):2585–94. doi:https://doi.org/10.2174/0929867324666170127095832
   PubMed Web of Science ®Google Scholar
• Pandey K, Tripathi SK, Panda M, Biswal BK. Prooxidative activity of plumbagin induces apoptosis in human pancreatic ductal adenocarcinoma cells via intrinsic apoptotic pathway. Toxicol in Vitro. 2020;65:104788. doi:https://doi.org/10.1016/j.tiv.2020.104788
   PubMed Web of Science ®Google Scholar
• Duraipandy N, Dharunya G, Lakra R, Korapatti PS, Syamala Kiran M. Fabrication of plumbagin on silver nanoframework for tunable redox modulation: implications for therapeutic angiogenesis. J Cell Physiol. 2019;234(8):13110–27. doi:https://doi.org/10.1002/jcp.27981
   PubMed Web of Science ®Google Scholar
• Nambiar D, Prajapati V, Agarwal R, Singh RP. In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells. Cancer Lett. 2013;334(1):109–17. doi:https://doi.org/10.1016/j.canlet.2012.09.004
   PubMed Web of Science ®Google Scholar
• Zhang X, Jiang J, Chen Z, Cao M. Silibinin inhibited autophagy and mitochondrial apoptosis in pancreatic carcinoma by activating JNK/SAPK signaling. Pathol Res Pract. 2019;215(9):152530. doi:https://doi.org/10.1016/j.prp.2019.152530
   PubMed Web of Science ®Google Scholar
• Shukla SK, Dasgupta A, Mehla K, et al. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Oncotarget. 2015;6(38):41146–61. doi:https://doi.org/10.18632/oncotarget.5843
   PubMedGoogle Scholar
• Vargas-Mendoza N, Madrigal-Santillán E, Morales-González A, et al. Hepatoprotective effect of silymarin. World J Hepatol. 2014;6(3):144–9. doi:https://doi.org/10.4254/wjh.v6.i3.144
   PubMedGoogle Scholar
• Iqbal J, Abbasi BA, Mahmood T, Kanwal S, Ali B, Shah SA, Khalil AT. Plant-derived anticancer agents: a green anticancer approach. Asian Pac J Trop Biomed. 2017;7(12):1129–50. doi:https://doi.org/10.1016/j.apjtb.2017.10.016
   Web of Science ®Google Scholar
• Guo P, Cai C, Wu X, et al. An insight into the molecular mechanism of berberine towards multiple cancer types through systems pharmacology. Front Pharmacol. 2019;10:857.
   PubMed Web of Science ®Google Scholar
• Park SH, Sung JH, Chung N. Berberine diminishes side population and down-regulates stem cell-associated genes in the pancreatic cancer cell lines PANC-1 and MIA PaCa-2. Mol Cell Biochem. 2014;394(1-2):209–15. doi:https://doi.org/10.1007/s11010-014-2096-1
   PubMed Web of Science ®Google Scholar
• Park SH, Sung JH, Kim EJ, Chung N. Berberine induces apoptosis via ROS generation in PANC-1 and MIA-PaCa2 pancreatic cell lines. Braz J Med Biol Res. 2015;48(2):111–9. doi:https://doi.org/10.1590/1414-431X20144293
   PubMed Web of Science ®Google Scholar
• Liu J, Liu P, Xu T, et al. Berberine induces autophagic cell death in acute lymphoblastic leukemia by inactivating AKT/mTORC1 signaling. Drug Des Devel Ther. 2020;14:1813–23. doi:https://doi.org/10.2147/DDDT.S239247
   PubMed Web of Science ®Google Scholar
• Kisfalvi K, Sinnett-Smith J, Young SH, Eibl G, Rozengurt E. Berberine inhibits the growth of human pancreatic cancer cells in vitro and in vivo. Gastroenterology. 2012;142(5):S-907. doi:https://doi.org/10.1016/S0016-5085(12)63521-5
   PubMed Web of Science ®Google Scholar
• Akula SM, Candido S, Libra M, et al. Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells. Adv Biol Regul. 2019;73:100633. doi:https://doi.org/10.1016/j.jbior.2019.04.003
   PubMedGoogle Scholar
• Abrams SL, Follo MY, Steelman LS, et al. Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells. Adv Biol Regul. 2019;71:172–82. doi:https://doi.org/10.1016/j.jbior.2018.10.003
   PubMedGoogle Scholar
• Piao XM, Huo Y, Kang JP, Mathiyalagan R, Zhang H, Yang DU, Kim M, Yang DC, Kang SC, Wang YP. Diversity of ginsenoside profiles produced by various processing technologies. Molecules. 2020;25(19):4390. doi:https://doi.org/10.3390/molecules25194390
   PubMed Web of Science ®Google Scholar
• Yun TK, Choi SY. Preventive effect of ginseng intake against various human cancers: a case-control study on 1987 pairs. Cancer Epidemiol Biomarkers Prev. 1995;4(4):401–8.
   PubMed Web of Science ®Google Scholar
• Elshafay A, Tinh NX, Salman S, et al. Ginsenoside Rk1 bioactivity: a systematic review. PeerJ. 2017;5:e3993. doi:https://doi.org/10.7717/peerj.3993
   PubMed Web of Science ®Google Scholar
• Wang L, Xu J, Yan Y, Liu H, Li F. Synthesis of gold nanoparticles from leaf Panax notoginseng and its anticancer activity in pancreatic cancer PANC-1 cell lines. Artif Cells Nanomed Biotechnol. 2019;47(1):1216–23. doi:https://doi.org/10.1080/21691401.2019.1593852
   PubMed Web of Science ®Google Scholar
• Cheung SS, Tai J, Hasman D, Ou D, Warnock GL. Inhibition of human pancreatic cancer cell proliferation by Devil’s club oplopanax horridus and its polyacetylene bioactive compound. Nutr Cancer. 2015;67(6):954–64. doi:https://doi.org/10.1080/01635581.2015.1055367
   PubMed Web of Science ®Google Scholar
• Qian M, Yi L, Song-Lin L, Jie Y, Ping-Hu Z, Qiang W. Chemical profiles and anticancer effects of saponin fractions of different polarity from the leaves of Panax notoginseng. Chin J Nat Med. 2014;12(1):30–7. doi:https://doi.org/10.1016/S1875-5364(14)60006-6
   PubMed Web of Science ®Google Scholar
• Hao M, Wang W, Zhao Y, Zhang R, Wang H. Pharmacokinetics and tissue distribution of 25-hydroxyprotopanaxadiol, an anti-cancer compound isolated from Panax ginseng, in athymic mice bearing xenografts of human pancreatic tumors. Eur J Drug Metab Pharmacokinet. 2011;35(3-4):109–13. doi:https://doi.org/10.1007/s13318-010-0022-9
   PubMed Web of Science ®Google Scholar
• Wang P, Zhang L, Yao J, Shi Y, Li P, Ding K. An arabinogalactan from flowers of Panax notoginseng inhibits angiogenesis by BMP2/Smad/Id1 signaling. Carbohydr Polym. 2015;121:328–35. doi:https://doi.org/10.1016/j.carbpol.2014.11.073
   PubMed Web of Science ®Google Scholar
• Ju C, Jeon SM, Jun HS, Moon CK. Diol-ginsenosides from Korean Red Ginseng delay the development of type 1 diabetes in diabetes-prone biobreeding rats. J Ginseng Res. 2020;44(4):619–26. doi:https://doi.org/10.1016/j.jgr.2019.06.001
   PubMed Web of Science ®Google Scholar
• Lee S, Park J-M, Jeong M, Han Y-M, Go EJ, Ko WJ, Cho JY, Kwon CI, Hahm KB. Korean red ginseng ameliorated experimental pancreatitis through the inhibition of hydrogen sulfide in mice. Pancreatology. 2016;16(3):326–36. doi:https://doi.org/10.1016/j.pan.2016.02.012
   PubMed Web of Science ®Google Scholar
• Chian S, Zhao Y, Xu M, Yu X, Ke X, Gao R, Yin L. Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway. Anticancer Drugs. 2019;30(8):838–45. doi:https://doi.org/10.1097/CAD.0000000000000781
   PubMed Web of Science ®Google Scholar
• Wang SH, Wang YC, Nie YL, et al. Antiproliferative activity of the Chinese medicinal compound, delisheng, compared with rg3 and gemcitabine in HepG2 cells. Indian J Pharm Sci. 2013;75(5):578–84.
   PubMed Web of Science ®Google Scholar
• Wang W, Wang H, Rayburn ER, Zhao Y, Hill DL, Zhang R. 20(S)-25-methoxyl-dammarane-3beta, 12beta, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action. Br J Cancer. 2008;98(4):792–802. doi:https://doi.org/10.1038/sj.bjc.6604227
   PubMed Web of Science ®Google Scholar
• Miller AL, Garcia PL, Yoon KJ. Developing effective combination therapy for pancreatic cancer: an overview. Pharmacol Res. 2020;155:104740. doi:https://doi.org/10.1016/j.phrs.2020.104740
   PubMed Web of Science ®Google Scholar
• Elwood PC, Pickering JE, Morgan G, Galante J, Weightman AL, Morris D, Longley M, Mason M, Adams R, Dolwani S, et al. Systematic review update of observational studies further supports aspirin role in cancer treatment: time to share evidence and decision-making with patients?PLoS One. 2018;13(9):e0203957. doi:https://doi.org/10.1371/journal.pone.0203957
   PubMed Web of Science ®Google Scholar
• Hua H, Zhang H, Kong Q, Wang J, Jiang Y. Complex roles of the old drug aspirin in cancer chemoprevention and therapy. Med Res Rev. 2019;39(1):114–45. doi:https://doi.org/10.1002/med.21514
   PubMed Web of Science ®Google Scholar
• Costa AC, Reina-Couto M, Albino-Teixeira A, Sousa T. Aspirin and blood pressure: effects when used alone or in combination with antihypertensive drugs. Rev Port Cardiol. 2017;36(7-8):551–67. doi:https://doi.org/10.1016/j.repc.2017.05.008
   PubMedGoogle Scholar
• García Rodríguez LA, Martín-Pérez M, Hennekens CH, Rothwell PM, Lanas A. Bleeding risk with long-term low-dose aspirin: a systematic review of observational studies. PLoS One. 2016;11(8):e0160046. doi:https://doi.org/10.1371/journal.pone.0160046
   PubMed Web of Science ®Google Scholar
• Risch HA, Lu L, Streicher SA, Wang J, Zhang W, Ni Q, Kidd MS, Yu H, Gao Y-T. Aspirin use and reduced risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2017;26(1):68–74. doi:https://doi.org/10.1158/1055-9965.EPI-16-0508
   PubMed Web of Science ®Google Scholar
• Bosetti C, Santucci C, Gallus S, Martinetti M, La Vecchia C. Aspirin and the risk of colorectal and other digestive tract cancers: an updated meta-analysis through 2019. Ann Oncol. 2020;31(5):558–68. doi:https://doi.org/10.1016/j.annonc.2020.02.012
   PubMed Web of Science ®Google Scholar
• Mitrugno A, Sylman JL, Ngo ATP, Pang J, Sears RC, Williams CD, McCarty OJT. Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: implications for the oncoprotein c-MYC. Am J Physiol Cell Physiol. 2017;312(2):C176–C189. doi:https://doi.org/10.1152/ajpcell.00196.2016
   PubMed Web of Science ®Google Scholar
• Qiao Y, Yang T, Gan Y, Li W, Wang C, Gong Y, Lu Z. Associations between aspirin use and the risk of cancers: a meta-analysis of observational studies. BMC Cancer. 2018;18(1):288. doi:https://doi.org/10.1186/s12885-018-4156-5
   PubMed Web of Science ®Google Scholar
• Zhang Y, Liu L, Fan P, et al. Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer. Oncotarget. 2015;6(12):9999–10015. doi:https://doi.org/10.18632/oncotarget.3171
   PubMedGoogle Scholar
• Choi JH, Lee SH, Huh G, Chun JW, You MS, Paik WH, Ryu JK, Kim Y-T. The association between use of statin or aspirin and pancreatic ductal adenocarcinoma: a nested case-control study in a Korean nationwide cohort. Cancer Med. 2019;8(17):7419–30. doi:https://doi.org/10.1002/cam4.2617
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31–41. doi:https://doi.org/10.1016/S0140-6736(10)62110-1
   PubMed Web of Science ®Google Scholar
• Zhang YP, Wan YD, Sun YL, Li J, Zhu RT. Aspirin might reduce the incidence of pancreatic cancer: a meta-analysis of observational studies. Sci Rep. 2015;5(1):15460. doi:https://doi.org/10.1038/srep15460
   PubMed Web of Science ®Google Scholar
• Plassmeier L, Knoop R, Waldmann J, Kesselring R, Buchholz M, Fichtner-Feigl S, Bartsch DK, Fendrich V. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer. Langenbecks Arch Surg. 2013;398(7):989–96. doi:https://doi.org/10.1007/s00423-013-1105-2
   PubMed Web of Science ®Google Scholar
• Ou YQ, Zhu W, Li Y, et al. Aspirin inhibits proliferation of gemcitabine-resistant human pancreatic cancer cells and augments gemcitabine-induced cytotoxicity. Acta Pharmacol Sin. 2010;31(1):73–80. doi:https://doi.org/10.1038/aps.2009.172
   PubMed Web of Science ®Google Scholar
• Bassani-Sternberg M, Digklia A, Huber F, et al. A Phase Ib study of the combination of personalized autologous dendritic cell vaccine, aspirin, and standard of care adjuvant chemotherapy followed by nivolumab for resected pancreatic adenocarcinoma: a proof of antigen discovery feasibility in three patients. Front Immunol. 2019;10:1832.
   PubMed Web of Science ®Google Scholar
• Gou S, Cui P, Li X, et al. Low concentrations of metformin selectively inhibit CD133+ cell proliferation in pancreatic cancer and have anticancer action. PLoS One. 2013;8(5):e63969. doi:https://doi.org/10.1371/journal.pone.0063969
   PubMed Web of Science ®Google Scholar
• Zhou PT, Li B, Liu FR, et al. Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis. Oncotarget. 2017;8(15):25242–50. doi:https://doi.org/10.18632/oncotarget.15692
   PubMedGoogle Scholar
• Dong YW, Shi YQ, He LW, Cui XY, Su PZ. Effects of metformin on survival outcomes of pancreatic cancer: a meta-analysis. Oncotarget. 2017;8(33):55478–88. doi:https://doi.org/10.18632/oncotarget.18233
   PubMedGoogle Scholar
• Griss T, Vincent EE, Egnatchik R, et al. Metformin antagonizes cancer cell proliferation by suppressing mitochondrial-dependent biosynthesis. PLoS Biol. 2015;13(12):e1002309. doi:https://doi.org/10.1371/journal.pbio.1002309
   PubMed Web of Science ®Google Scholar
• Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, Steele VE, Rao CV. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. Transl Oncol. 2013;6(6):649–59. doi:https://doi.org/10.1593/tlo.13556
   PubMed Web of Science ®Google Scholar
• Incio J, Suboj P, Chin SM, et al. Metformin reduces desmoplasia in pancreatic cancer by reprogramming stellate cells and tumor-associated macrophages. PLoS One. 2015;10(12):e0141392. doi:https://doi.org/10.1371/journal.pone.0141392
   PubMed Web of Science ®Google Scholar
• Han H, Hou Y, Chen X, et al. Metformin-induced stromal depletion to enhance the penetration of gemcitabine-loaded magnetic nanoparticles for pancreatic cancer targeted therapy. J Am Chem Soc. 2020;142(10):4944–54. doi:https://doi.org/10.1021/jacs.0c00650
   PubMed Web of Science ®Google Scholar
• Peng M, Darko KO, Tao T, et al. Combination of metformin with chemotherapeutic drugs via different molecular mechanisms. Cancer Treat Rev. 2017;54:24–33. doi:https://doi.org/10.1016/j.ctrv.2017.01.005
   PubMed Web of Science ®Google Scholar
• Zhou HY, Yao XM, Chen XD, et al. Mechanism of metformin enhancing the sensitivity of human pancreatic cancer cells to gem-citabine by regulating the PI3K/Akt/mTOR signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(23):10283–9.
   PubMed Web of Science ®Google Scholar
• Li X, Li T, Liu Z, Gou S, Wang C. The effect of metformin on survival of patients with pancreatic cancer: a meta-analysis. Sci Rep. 2017;7(1):5825. doi:https://doi.org/10.1038/s41598-017-06207-x
   PubMed Web of Science ®Google Scholar
• Suzuki K, Takeuchi O, Suzuki Y, Kitagawa Y. Mechanisms of metformin’s anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma. Int J Oncol. 2019;54(2):764–72.
   PubMed Web of Science ®Google Scholar
• Qian W, Li J, Chen K, et al. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Life Sci. 2018;208:253–61. doi:https://doi.org/10.1016/j.lfs.2018.07.046
   PubMed Web of Science ®Google Scholar
• Fasih A, Elbaz HA, Hüttemann M, Konski AA, Zielske SP. Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway. Radiat Res. 2014;182(1):50–9. doi:https://doi.org/10.1667/RR13568.1
   PubMed Web of Science ®Google Scholar
• Shi Y, He Z, Jia Z, Xu C. Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo. Mol Med Rep. 2016;14(4):2921–8. doi:https://doi.org/10.3892/mmr.2016.5592
   PubMed Web of Science ®Google Scholar
• Candido S, Abrams SL, Steelman L, et al. Metformin influences drug sensitivity in pancreatic cancer cells. Adv Biol Regul. 2018;68:13–30. doi:https://doi.org/10.1016/j.jbior.2018.02.002
   PubMedGoogle Scholar
• Baron B, Wang Y, Maehara S, et al. Resistance to gemcitabine in the pancreatic cancer cell line KLM1-R reversed by metformin action. Anticancer Res. 2015;35(4):1941–9.
   PubMed Web of Science ®Google Scholar
• Zechner D, Albert AC, Bürtin F, Vollmar B. Metformin inhibits gemcitabine induced apoptosis in pancreatic cancer cell lines. J Cancer. 2017;8(10):1744–9. doi:https://doi.org/10.7150/jca.17972
   PubMed Web of Science ®Google Scholar
• Chai X, Chu H, Yang X, et al. Metformin increases sensitivity of pancreatic cancer cells to gemcitabine by reducing CD133+ cell populations and suppressing ERK/P70S6K signaling. Sci Rep. 2015;5:14404. doi:https://doi.org/10.1038/srep14404
   PubMed Web of Science ®Google Scholar
• Braghiroli MI, de Celis Ferrari AC, Pfiffer TE, et al. Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas. Ecancermedicalscience. 2015;9:563. doi:https://doi.org/10.3332/ecancer.2015.563
   PubMed Web of Science ®Google Scholar
• Reni M, Dugnani E, Cereda S, et al. (Ir)relevance of metformin treatment in patients with metastatic pancreatic cancer: an open-label, randomized phase II trial. Clin Cancer Res. 2016;22(5):1076–85. doi:https://doi.org/10.1158/1078-0432.CCR-15-1722
   PubMed Web of Science ®Google Scholar
• Djamgoz M, Plant J. 2014. Beat cancer: how to regain control of your health and your life. London: Vermilion (Ebury Publishing).
   Google Scholar
• Zhang D, Wu J, Liu S, Zhang X, Zhang B. Network meta-analysis of Chinese herbal injections combined with the chemotherapy for the treatment of pancreatic cancer. Medicine (Baltimore). 2017;96(21):e7005. doi:https://doi.org/10.1097/MD.0000000000007005
   PubMed Web of Science ®Google Scholar
• Ladas EJ, Kroll DJ, Oberlies NH, et al. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer. 2010;116(2):506–13. doi:https://doi.org/10.1002/cncr.24723
   PubMed Web of Science ®Google Scholar